PI(3)King the Right Target
PI(3)King the right target after CDK4/6 inhibitors fail patients is an exciting area of research and FDA approval. Now that there are multiple options approved by the FDA and more to come, patients have more treatment choices. Join host Abigail Johnston as she interviews 2 patients who give us their perspective on these advances, as well as a doctor whose scientific research has led the way identifying PIK3CA mutations as a cancer genomic biomarker.
Report Back From ASCO 2023: What’s the Latest News in MBC Research?
Dr. Sherry Shen, breast oncologist from Memorial Sloan Kettering Cancer Center, breaks down the recent research from the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting. She will present new findings in Metastatic Breast Cancer research.
OMBCL Shorts #2: Dr. Erika Hamilton with Top Takeaways from ASCO23
Our second OMBCL Shorts features Dr. Erika Hamilton answering questions about her top takeaways from ASCO23. In this 20-minute interview we covered important updates on the CDK4/6 inhibitors for both early-stage and metastatic breast cancer, as well as research on a new HER3 ADC and the first AKT inhibitor for MBC.
OMBCL Shorts #1: Dr. Stephanie Graff & Her Steps For Those Newly Diagnosed MBC
Our inaugural OMBCL Shorts features Dr. Stephanie Graff talking about what she does when someone is newly diagnosed with MBC. This season, we had a 3-part series for people newly diagnosed and we couldn't resist getting her take on the topic. And we're so glad we asked!
Recent Advances, Controversies, and Emerging Trends in MBC
Over the last 20 years, advances in HER2 targeting treatments, antibody-drug conjugates (ADCs), immune checkpoint inhibitors (ICIs), and cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have prolonged survival and changed the breast cancer treatment landscape. Success leads to more questions about optimal drug sequencing, mechanisms of resistance, and how to overcome that resistance. Let’s ask Dr. Stephanie Graff to help us tackle these topics and more.
ASCO 2022: When The Dust Settles, What Are My Treatment Options For ER+/HER2- MBC?
Welcome to the second part of our post–2022-ASCO analysis of the state of affairs in the HR-positive MBC. It was not so long ago that our only options were single-agent endocrine therapy and systemic chemo. We have come a long way over the last couple of decades. Today we are asking Drs. Stephanie Graff, Sara Hurvitz, and Kevin Kalinsky to talk about how they make decisions in the clinic in selecting and sequencing treatments, specifically CDK4/6 inhibitors and the newly approved targeted therapies.
RTAC: FES/Cerianna Screening for Estrogen Positive MBC
There’s a FDA- approved diagnostic imaging agent developed to comprehensively evaluate estrogen receptor-positive (ER+) lesions in recurrent or metastatic breast cancer as an adjunct to biopsy. By creating a “whole-body” picture of ER+ lesions, Cerianna may be a helpful diagnostic tool in helping oncologists better determine the most appropriate course of treatment. Learn more in this episode.
ASCO 2022: When the Dust Settles, Will ADCs Change MBC?
While HER2-Low and DESTINY-Breast04 garnered most of the headlines from the ASCO 2022 in June, it was not the only reason for optimism. Our MBC Life takes a deeper dive with Dr. Stephanie Graff and Dr. Hope Rugo in this first episode of our two-part series.
Report Back from ASCO 2022: What’s the Latest in MBC Research?
The biggest cancer conference in the world, the American Society of Clinical Oncology (ASCO) 2022 annual meeting, was back in person after 2 years online during the COVID pandemic. Some of the research highlights presented this year are “practice-changing.” and received a rarely given standing ovation. What is practice changing in MBC? Get the answer to this question and a lot more in the report back from ASCO
Dr. Nancy Lin: Are CNS Mets Becoming More Treatable? What’s New with STOP-HER2?
Brain metastases are unfortunately an all too common and devastating complication of breast cancer. The blood-brain barrier has long been a key obstacle to developing effective systemic therapies; however, newer agents are showing signs of overcoming this challenge. Dr. Nancy Lin explains.
ER Progression and Resistance: Causes, Consequences, and Hope
Endocrine therapy is an effective way to treat hormone-sensitive breast cancers, but de novo and acquired resistance to this treatment remains a major challenge. In this episode, the Our MBC Life team hears from two dynamic MSK oncologists Dr. Pedram Razavi and Dr. Komal Jhaveri on treatment strategies and the latest research around the problem of endocrine resistance.
Dr. Stephanie Graff: Understanding Progression
What does it mean when our cancer shows progression? And how do we know when that happens? The Our MBC Life team gets the lowdown from Dr. Stephanie L. Graff.
Dr. Timothy Pluard: the Future of MBC Care is Already Here
The future of personalized care for those living with MBC is already here, and it is happening in Kansas City, Missouri. Dr. Timothy Pluard, Medical Director of the Kansas City’s Saint Luke’s Koontz Center for Advanced Breast Cancer is with us today and we’ll ask him how he and his team create an individualized, completely comprehensive plan for each woman.
Report Back from SABCS 2021: What’s the Latest in MBC Research?
Learn about the most recent information released at the annual San Antonio Breast Cancer Symposium regarding metastatic breast cancer research with Dr. Peter Schmid, Professor of Cancer Medicine at Barts Cancer Institute in London, England. Dr. Schmid will provide a comprehensive update and answer your questions about these new developments.
Road to a Cure - drug resistance
It is fitting that our 7th and last stop before the SABCS is back to NYC. Co-hosts Lisa Laudico and Ellen Landsberger talk with Dr Sarat Chandarlapaty, a leading Physician Scientist at MSKCC. As both a physician treating patients and a scientist in the lab, Dr. Chandarlapaty gives us an understanding of translational medicine, transferring what he learns from his patients back into the lab to answer questions that advance the treatment of metastatic breast cancer.
Road to a Cure - Dr. Sara Hurvitz
The Road to a Cure series gets on the redeye to LA to have Senior Producer and Co-host, Victoria Goldberg and co-host Kate Pfitzer speak with Dr. Sara Hurvitz. She talks about her perspective on where we are as we work for a cure, the HER2+ studies she is excited about, and other research that is intriguing as it relates to all subtypes